New Delhi, June 23 -- Danish drugmaker Novo Nordisk A/S said on Monday it is terminating a recently formed obesity-drug partnership with Hims & Hers Health Inc, citing concerns about sales of compounded drugs and misleading marketing.
The partnership had been touted as a way to boost obesity-drug sales in the US.
Shares of Hims & Hers plunged 18% in trading before US stock exchanges opened. Novo lost as much as 5% in Copenhagen.
Published by HT Digital Content Services with permission from MINT....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.